American Origin Unverified
This profile is unclaimed and has not been independently reviewed.
Claim & get verified
CH
Churchill Capital Corp XI
$10.29
+0.00%
NASDAQ: CCXI · 15-min delayed
$573.2MMarket cap
$382.1KNet income
CCXINASDAQ
2026IPO
About Churchill Capital Corp XI
Churchill Capital Corp XI is a blank check company.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Reported figures
Financial summary
- Net income
- $382.1K
- Total assets
- $415.9M
- Market cap
- $573.2M
- Operating margin
- -403.2%
- Net margin
- -408.9%
Source: SEC EDGAR · updated Jun 8, 2026
Multi-year
Revenue & profit trend
FY2017
FY2018
FY2019
FY2020
FY2021
Revenue Net income
FY 2021
Financial statements
Income statement
- Revenue
- $32.2M
- Operating expenses
- $162.1M
- Operating income
- -$129.9M
- Income tax
- $0
- Net income
- -$131.8M
Balance sheet
- Total assets
- $425.7M
- Current assets
- $269.2M
- Total liabilities
- $139.5M
- Current liabilities
- $63.0M
- Shareholders’ equity
- $286.1M
Cash flow
- Operating cash flow
- -$75.6M
- Investing cash flow
- $92.2M
- Financing cash flow
- $1.1M
- Net cash flow
- $17.7M
Statements via Polygon.io (SEC filings)
NASDAQ: CCXI
$10.29
+0.00%
15-minute delayed · data by Polygon.io
Past year
$10.09
$10.29
52-week range
- Market cap
- $573.2M
- Shares outstanding
- 55.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 9, 2026
Market data by Polygon.io · prices are 15-minute delayed
Auto-generated
At a glance
- Profitable — net income of $382.1K.
- Revenue declined 61% from FY2017 to FY2021.
- Trading near its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Churchill Capital Corp XI.
Write a review
Newsroom
News about Churchill Capital Corp XI
ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings
Is ChemoCentryx (CCXI) Stock Outpacing Its Medical Peers This Year?
ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
Why Is Ionis Pharmaceuticals (IONS) Down 5.8% Since Last Earnings Report?
News & sentiment via Polygon.io
Explore
Browse all →
